Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy
New England Journal of Medicine · 11.01.2024 · 390 (2) · 132-142
DOI: 10.1056/nejmoa2305434 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 11.01.2024. Verfasst von Julian D Gillmore und 24 weiteren Autor:innen. Beteiligte Einrichtung: From the National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital, London (J.D.G., M.F.); the Medical Univer…. Hauptthemen laut MEDLINE: Amyloidosis, Cardiomyopathies, Prealbumin, Cardiovascular Agents. Die Arbeit wurde bisher 592-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: Eidos Therapeutics.
Abstract (Originalsprache)
BACKGROUND: Transthyretin amyloid cardiomyopathy is characterized by the deposition of misfolded monomeric transthyretin (TTR) in the heart. Acoramidis is a high-affinity TTR stabilizer that acts to inhibit dissociation of tetrameric TTR and leads to more than 90% stabilization across the dosing interval as measured ex vivo. METHODS: In this phase 3, double-blind trial, we randomly assigned patients with transthyretin amyloid cardiomyopathy in a 2:1 ratio to receive acoramidis hydrochloride at a dose of 800 mg twice daily or matching placebo for 30 months. Efficacy was assessed in the patients who had an estimated glomerular filtration rate of at least 30 ml per minute per 1.73 m2 of body-surface area. The four-step primary hierarchical analysis included death from any cause, cardiovascular-related hospitalization, the change from baseline in the N-terminal pro-B-type natriuretic peptide (NT-proBNP) level, and the change from baseline in the 6-minute walk distance. We used the Finkelstein-Schoenfeld method to compare all potential pairs of patients within strata to generate a P value. Key secondary outcomes were death from any cause, the 6-minute walk distance, the score on the Kansas City Cardiomyopathy Questionnaire-Overall Summary, and the serum TTR level. RESULTS: A total of 632 patients underwent randomization. The primary analysis favored acoramidis over placebo (P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital, London (J.D.G., M.F.); the Medical University of South Carolina, Charleston, SC (D.P.J.); Tuscan Regional Amylo…
ORCID-Profile: Mathew S Maurer
Förderung
- Eidos Therapeutics
Zitieren
APA
Gillmore, J. D., Judge, D. P., Cappelli, F., Fontana, M., Garcia-Pavia, P., Gibbs, S., Grogan, M., Hanna, M., Hoffman, J., Masri, A., Maurer, M. S., Nativi-Nicolau, J., Obici, L., Poulsen, S. H., Rockhold, F., Shah, K. B., Soman, P., Garg, J., Chiswell, K., …, & ATTRibute-CM Investigators (2024). Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy. New England Journal of Medicine, 390(2), 132-142. https://doi.org/10.1056/nejmoa2305434
Vancouver
Gillmore JD, Judge DP, Cappelli F, Fontana M, Garcia-Pavia P, Gibbs S, et al. Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy. New England Journal of Medicine. 2024;390(2):132-142. doi:10.1056/nejmoa2305434
BibTeX
@article{Gillmore2024,
author = {Gillmore, Julian D and Judge, Daniel P and Cappelli, Francesco and Fontana, Marianna and Garcia-Pavia, Pablo and Gibbs, Simon and Grogan, Martha and Hanna, Mazen and Hoffman, James and Masri, Ahmad and Maurer, Mathew S and Nativi-Nicolau, Jose and Obici, Laura and Poulsen, Steen Hvitfeldt and Rockhold, Frank and Shah, Keyur B and Soman, Prem and Garg, Jyotsna and Chiswell, Karen and Xu, Haolin and Cao, Xiaofan and Lystig, Ted and Sinha, Uma and Fox, Jonathan C and ATTRibute-CM Investigators, ATTRibute-CM Investigators},
title = {Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy},
journal = {New England Journal of Medicine},
year = {2024},
volume = {390},
number = {2},
pages = {132--142},
doi = {10.1056/nejmoa2305434}
}
EUVIMED